Payment overview · 2025
General Payments
$265.03
13 reported records · 9 companies
Healthcare provider profile · identity verified
Lora Plumlee Boone, DO
Allopathic & Osteopathic Physicians|Family Medicine · MANSFIELD, TX · NPI 1134414915
Verified facts
What the public records show
CMS Open Payments records show Lora Plumlee Boone, DO received $265.03 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.10 | 28.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.06 | 16.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.16 | 12.5% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $21.17 | 8.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.07 | 7.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.83 | 7.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.63 | 7.4% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $16.55 | 6.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.46 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $265.03 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.46 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 60 |
| Losartan Potassium | Losartan Potassium | 179 | 55 |
| Omeprazole | Omeprazole | 155 | 43 |
| Lisinopril | Lisinopril | 135 | 38 |
| Metformin Hcl | Metformin Hcl | 130 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 121 | 44 |
| Gabapentin | Gabapentin | 115 | 32 |
| Montelukast Sodium | Montelukast Sodium | 113 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 24 |
| Alprazolam | Alprazolam | 90 | 30 |
| Trazodone Hcl | Trazodone Hcl | 90 | 24 |
| Sertraline Hcl | Sertraline Hcl | 89 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 26 |
| Alendronate Sodium | Alendronate Sodium | 74 | 25 |
| Meloxicam | Meloxicam | 72 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 19 |
| Ozempic | Semaglutide | 67 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 17 |
| Tramadol Hcl | Tramadol Hcl | 64 | 26 |
| Glimepiride | Glimepiride | 62 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 19 |
| Bupropion Xl | Bupropion Hcl | 49 | 18 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Methocarbamol | Methocarbamol | 45 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 34 |
| Furosemide | Furosemide | 41 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Simvastatin | Simvastatin | 36 | 12 |
| Glipizide Er | Glipizide | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | 11 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | 11 |
| Azelastine Hcl | Azelastine Hcl | 26 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Azithromycin | Azithromycin | 25 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $265.03 · 13 records | GlaxoSmithKline, LLC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, INSPIRE, MOUNJARO, PAXLOVID, PREVNAR 20, Paradise Ultrasound Renal Denervation System, Prospera, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error